Mateon’s phase 2 global study for OT-101/ TGF- Inhibitor against COVID-19 cleared for patient enrollment in Argentina
On Oct. 19, 2020, Mateon Therapeutics announced the receipt of approval from Republica Argentina Poder Ejecutivo Nacional, the…
On Oct. 19, 2020, Mateon Therapeutics announced the receipt of approval from Republica Argentina Poder Ejecutivo Nacional, the…
On Oct. 19, 2020, researchers at MIT, Harvard, and the Broad Institute of MIT announced they had developed…
On Oct. 19, 2020, ICON announced that it had been re-selected by the Biomedical Advanced Research and Development…
On Oct. 19, 2020, Evotec announced that its Seattle-based subsidiary, Just – Evotec Biologics had received a grant…
On Oct. 15, 2020, the World Health Organization (WHO) announced Interim that results from the Solidarity Therapeutics Trial,…
On Oct. 15, 2020, Tonix Pharmaceuticals announced that the first participant was enrolled in the observational PRECISION study…
On Nov. 9, 2020, after more than two years of reconstruction efforts, scientists from the Fred Hutchinson Cancer…
On Oct. 14, 2020, the FDA approved Regeneron Pharmaceutical’s Inmazeb (atoltivimab, maftivimab, and odesivimab-ebgn), a mixture of three…
On Oct. 14, 2020, 3M and Discovery Education announced they had named 14-year-old Anika Chebrolu from Frisco, Texas,…
On Oct. 14, 2020, Regeneron announced that the FDA had approved Inmazeb (atoltivimab, maftivimab and odesivimab-ebgn) for the…
On Oct. 13, 2020, Howard Hughes Medical Institute Investigator Leslie Vosshall’s team at The Rockefeller University and colleagues…
On Oct. 13, 2020, Humanigen announced that the National Institute of Allergy and Infectious Diseases (NIAID), had launched…
On Oct. 13, 2020, RedHill Biopharma announced collaborations with two specialist pharmaceutical manufacturers in Europe and Canada to…
On Oct. 12, 2020, the Washington University School of Medicine in St. Louis announced a $14.6 million grant…
On Oct. 8, 2020, the relation between COVID-19 and Guillain-Barre syndrome in adults: a systematic review was published…
On Oct. 8, 2020, the La Jolla Institute for Immunology (LJI) announced it had been granted $1.4 million…
On Oct. 8, 2020, Eli Lilly and the Bill & Melinda Gates Foundation, as part of the COVID-19…
On Oct. 8, 2020, SIGA Technologies announced that the Public Health Agency of Canada (PHAC) has issued an…
On Oct. 7, 2020, the Nobel Prize in Chemistry 2020 was awarded to Emmanuelle Charpentier and Jennifer Doudna…
On Oct. 7, 2020, RedHill Biopharma announced that the U.S. Phase 2 study with opaganib (Yeliva, ABC294640)1 in…
On Oct. 7, 2020, RedHill Biopharma announced that the U.S. Phase 2 study with opaganib (Yeliva, ABC294640)1 in…
On Oct. 7, 2020, Sorrento Therapeutics announced that it had discovered a small molecule termed Salicyn-30 that demonstrated…
On Oct. 7, 2020, Mateon Therapeutics announced the first patient enrolled this week in its Phase IV study…
On Oct. 6, 2020, the National Institutes of Health (NIH), working in collaboration with the Biomedical Advanced Research…
On Oct. 6, 2020, Hologic announced that two studies in the Journal of Clinical Microbiology demonstrated the utility…
On Oct. 5, 2020, Mateon Therapeutics announced that ArtiShieldTM had been approved for manufacture and marketing by the…
On Oct. 1, 2020, Johnson & Johnson announced it had successfully completed its acquisition of Momenta Pharmaceuticals, a…
On Sept. 30, 2020, ViralClear Pharmaceuticals and Sorrento Therapeutics announced the companies were exploring the synergistic potential of…
On Sept. 30, 2020, Bio-Techne announced the opening of its approximately 61,000 square foot state-of-the-art GMP (Good Manufacturing…
On Sept. 30, 2020, the National Institutes of Health (NIH) announced funding of a nationwide study to discover…